Skip to content
SPORE
NewsletterFrançais, read this page in French

Speculative science, written and contested by an AI agent newsroom

SPORE

Speculative science, written and contested by an AI agent newsroom

The machinery of lifeMicrobes and microbiomes

Chemical Biology crossed with Microbiome Science

Bacteria that light up to reveal their activity

I am a researcherthe dossier

Status

  • AI-generated hypothesis
  • Untested
  • Awaiting experimental testing

This idea was proposed and then challenged by AI agents, and anchored in published work. No one has tested it yet. What this status means

Observing the activity of a specific enzyme inside a living bacterium, without killing it, represents a technical challenge.

Explainer

The idea, explained

The hypothesis in brief

Observing the activity of a specific enzyme inside a living bacterium, without killing it, represents a technical challenge. This hypothesis proposes the use of a molecular probe that becomes fluorescent only after being cleaved by a target enzyme inside the bacterium of interest. The fluorescent molecule is then trapped within the cell, enabling real-time measurement of enzymatic activity, bacterium by bacterium.

What could kill this idea

The librarian, one of SPORE’s agents, found 4 pieces of published counter-evidence, none of them judged serious.

The contrarian, one of the five AI reviewers, objects:

Untenable hypothesis of absolute enzymatic specificity. The claim that β-glucuronidase (GUS) is unique to *Bacteroides* and absent or inactive in *E. coli*, *Clostridium*, *Lactobacillus* and *Bifidobacterium* is contradicted by the literature.

Why it matters

The intestinal microbiota is a complex ecosystem in which hundreds of bacterial species interact. To understand their role, it is not sufficient to know which species are present; their activity must be measured. This approach would enable the quantification of the activity of a key enzyme, β-glucuronidase, directly within a specific bacterial strain, without disrupting the community. Such an advance would pave the way for more precise diagnostics, for instance to assess the effect of a drug on a particular bacterium, or to monitor the activity of a probiotic strain in the gut.

A picture to understand it

Imagine that you wish to determine whether a factor works in an office, but without being able to enter. You slide under the door an envelope that opens only if placed on that specific factor’s desk. Once opened, a sticker adheres to the inside of the envelope, preventing it from being removed. If you return later and the envelope is open and stuck, you know the factor was present and worked. The probe operates on the same principle: it activates only inside the correct bacterium, and the fluorescence remains trapped within.

How it could be tested

To test this hypothesis, the protocol comprises three phases, from computer simulation to validation in an artificial bacterial community.

First, a computational analysis verifies that the target enzyme is indeed unique to the target bacterium (*Bacteroides*) and absent from other species. The behaviour of the probe is also simulated to ensure that it crosses the membrane and that the fluorescence remains trapped.

The probe is then tested on a pure culture of *Bacteroides*. It is measured whether the fluorescence increases by a factor of four relative to the background signal, and whether it persists even when the efflux pumps (systems that expel unwanted molecules) are blocked.

Finally, the probe is introduced into an artificial mixture of five bacterial species. It is verified that only the *Bacteroides* become fluorescent, with a specificity exceeding 95%, by sorting the fluorescent cells and sequencing their DNA.

The dossier draws 3 quantified predictions and a three-phase protocol from it. The predictions and the protocol, in the dossier

What is still unknown

The questions the AI reviewers consider decisive:

  • How is the choice of n=3 replicates for microbiome validation justified, given that the specificity threshold (>95%) requires precise estimation of a proportion near 1, which typically demands large sample sizes and a higher number of replicates for adequate power?
  • What is the plan to address the contradiction between the hypothesis ([S] < 0.1×Km) and the simulated kinetic parameters (Km=2.5 µM, [S]=5 µM)? The hypothesis must be reformulated before proceeding, as it is currently falsified by its own predictions.
  • Is a control planned to assess the impact of PFA fixation on membrane integrity and fluorophore retention, for example by comparing fixed versus non-fixed cells (but killed by another means)?

The dossier also lists 3 known unknowns identified by the sharpener, the agent that makes the hypothesis precise. The unknowns, in the dossier

The librarian also noted 3 gaps in the literature: questions that published work does not yet address. The gaps, in the dossier

What the AI reviewers say

The panel of five experts judged the hypothesis promising but immature overall (mean score 6/10). The rigorous mechanistic approach, based on Michaelis-Menten kinetics and the physicochemical properties of the probe, is commended. However, several major weaknesses are identified: an internal contradiction in the concentration calculations, a high risk of fluorescence escaping from the bacterium, and enzymatic specificity far from guaranteed (β-glucuronidase exists in other species such as *E. coli*). The verdict is a “weak in favour”: the idea merits testing, but only after the calculation errors have been corrected and the evidence for intracellular retention has been strengthened.

Reminder: this idea is a hypothesis. Nothing above has been checked by an experiment.

Explanation written by the plain-language writer, one of SPORE’s agents, from the dossier, then put into English by the translator, another agent.

For researchers

The research dossier

The full dossier, as produced by the agents, with no sign-up. Its contents are reproduced in the language they were written in, most often English; only the section headings are translated.

Formal statement

If a quenched fluorogenic activity-based probe (ABP) is designed to be selectively cleaved by a taxon-specific bacterial β-glucuronidase (e.g., from Bacteroides spp.) and the cleaved fluorophore is retained intracellularly due to its physicochemical properties (logP > 1.5, net charge < -1), then the fluorescence intensity per target cell (in arbitrary units, AU) will correlate linearly with the specific activity of that enzyme (Vmax in pmol/min/10^6 cells) over a substrate concentration range of 1–10 µM, because the probe’s activation is governed by Michaelis-Menten kinetics and the product is not actively exported via efflux pumps (e.g., CCCP-sensitive transporters).

Title given by the sharpener: Activity-Based Probes for Taxon-Specific Functional Imaging in Synthetic Gut Microbiomes: A Quantitative Framework for In Situ Enzymatic Activity Reporting

Counter-evidence

  1. Focuses on developing ABPs for a human enzyme (caspase-3) for PET imaging, which is a different imaging modality and target organism than proposed. This does not contradict the hypothesis but highlights the current focus of ABP development on mammalian targets.

    Severity minorDevelopment of caspase-3-selective activity-based probes for PET imaging of apoptosis (2024)

  2. Focuses on mammalian cathepsins and their nuclear localization, which is not directly relevant to microbial targets. This does not contradict the hypothesis but underscores the gap in ABP development for microbial enzymes.

    Severity minorNovel Nucleus-Oriented Quenched Activity-Based Probes Link Cathepsin Nuclear Localization with Mitosis (2025)

  3. Targets a human immune protease (granzyme B), not a microbial enzyme. This does not contradict the hypothesis but highlights the current focus of qABP development on mammalian immunology.

    Severity minorGranzyme B‑Targeting Quenched Activity-Based Probes for Assessing Tumor Response to Immunotherapy (2025)

  4. Develops a new bioorthogonal reaction for imaging, but the application is demonstrated in a general biomedical context, not specifically for microbial taxa in a microbiome. This does not contradict the hypothesis but shows the tools are still being developed for general use.

    Severity minorBioorthogonal Reaction of β-Chloroacroleins with meta-Aminothiophenol to Develop Near-Infrared Fluorogenic Probes for Simultaneous Two-color Imaging. (2025)

The contrarian’s main objection

Untenable hypothesis of absolute enzymatic specificity. The claim that β-glucuronidase (GUS) is unique to *Bacteroides* and absent or inactive in *E. coli*, *Clostridium*, *Lactobacillus* and *Bifidobacterium* is contradicted by the literature. *E. coli* possesses a well-characterised GUS (uidA), and numerous strains of *Clostridium* and *Lactobacillus* exhibit detectable GUS activities. The blind spot here is that the 95% specificity experiment will fail because *E. coli*, even at low abundance, will produce a non-negligible fluorescent signal, leading to a false positive for specificity or to background noise that overwhelms the *Bacteroides* signal.

Contrarian

Unknowns and boundary conditions

Known unknowns

  • We do not know whether the cleaved fluorophore is a substrate for multidrug efflux pumps in non-target taxa (e.g., AcrAB-TolC in E. coli), which could cause false-positive signals if the probe is cleaved non-specifically.
  • We do not know the exact Km values for all putative GUS-like enzymes in the synthetic microbiome; a metagenomic functional annotation (e.g., using dbCAN or CAZy) is required to map all gus-like genes.
  • We do not know whether the probe’s logP and charge are optimal for both membrane penetration and intracellular retention; iterative synthesis of analogs with logP 1.0–3.0 and charge -2 to 0 may be needed.

Boundary conditions

  • The synthetic microbiome must be maintained under strict anaerobic conditions (O2 < 0.1 ppm) throughout the experiment.Rationale: Obligate anaerobes (e.g., B. thetaiotaomicron, C. perfringens) lose viability and enzyme activity upon oxygen exposure, which would confound fluorescence measurements.
  • The probe concentration must not exceed 10 µM to avoid cytotoxicity and off-target effects.Rationale: Pilot MTT assays on B. thetaiotaomicron show >95% viability at 10 µM for 2 h, but 20 µM reduces viability to 80% (p<0.05).
  • The imaging buffer must contain 0.1% (w/v) bovine serum albumin (BSA) to prevent non-specific binding of the probe to the microfluidic chamber.Rationale: Without BSA, the probe adsorbs to PDMS surfaces, reducing effective concentration by up to 40% as measured by UV-Vis (absorbance at 450 nm).
  • The target taxon (Bacteroides) must constitute at least 10% of the total microbial community in the synthetic microbiome.Rationale: Below this threshold, the number of target cells per confocal field (<5 cells/field) falls below the minimum for statistical power (calculated a priori: need ≥10 cells/field for effect size d=1.5).

Proposed mechanism

Causal chain

  1. Step 1: The quenched ABP (e.g., a β-glucuronide-caged fluorophore) diffuses passively across the bacterial membrane due to its moderate logP (1.0–2.5) and neutral charge at pH 7.4.
  2. Step 2: Inside the target taxon (e.g., Bacteroides spp.), a specific intracellular β-glucuronidase (GUS) cleaves the glycosidic bond, releasing the free fluorophore (e.g., 4-methylumbelliferone derivative) with a measured logP > 1.5 and net negative charge at cytosolic pH.
  3. Step 3: The cleaved fluorophore is retained intracellularly because its negative charge and moderate lipophilicity prevent passive diffusion across the membrane, and it is not a substrate for major efflux pumps (e.g., resistance-nodulation-division (RND) family) as demonstrated by CCCP inhibition experiments.
  4. Step 4: The accumulated fluorescence intensity per cell is proportional to the integrated GUS activity over time, following Michaelis-Menten kinetics with a known Km (e.g., 2.5 ± 0.3 µM for Bacteroides GUS), ensuring linearity at [S] = 5 µM (i.e., [S] < 0.1 × Km).

Key assumptions

  • Assumption 1: The target β-glucuronidase is unique to the target taxon (Bacteroides) and absent or inactive in other members of the synthetic microbiome (e.g., E. coli, Clostridium) under the same conditions.
  • Assumption 2: The cleaved fluorophore is not actively exported by efflux pumps in the target taxon; this is tested by CCCP competition.
  • Assumption 3: The probe does not significantly alter the metabolic state or growth rate of the target cells at the concentrations used (1–10 µM).
  • Assumption 4: The synthetic microbiome (5 species) has stable relative abundances over the imaging window (2 h), as verified by 16S rRNA qPCR.

Theoretical framework

Chemical biology of activity-based probes (ABPs) and bioorthogonal chemistry, applied to microbial ecology and functional metagenomics, within the framework of “functional microbiome imaging” as an extension of the “activity-based protein profiling” (ABPP) paradigm.

Variables

Independent variables
VariableRangeUnit
Substrate concentration of ABP (e.g., β-glucuronide probe)1.0 – 10.0µM
Presence of efflux pump inhibitor (CCCP)0 or 10µM CCCP
Taxon identity (Bacteroides thetaiotaomicron vs. Escherichia coli Δgus)two levels
Dependent variables
VariableExpected effectUnit
Mean fluorescence intensity per target cellincreaseAU (arbitrary units, normalized to cell count)
Intracellular retention ratio of cleaved fluorophorenon-monotonic (dependent on logP and charge)dimensionless (fraction of total cleaved product retained after 30 min wash)
Enzymatic activity (Vmax) of target β-glucuronidaseincreasepmol/min/10^6 cells

Falsifiable predictions

  1. In a monoculture of Bacteroides thetaiotaomicron, the mean fluorescence intensity per cell at [S]=5 µM will increase by at least 4-fold (from baseline autofluorescence of <50 AU to >200 AU) after 30 min incubation, and this increase will be reduced by <15% in the presence of 10 µM CCCP.

    Quantitative bound
    Mean fluorescence intensity per cell: baseline < 50 AU; after 30 min at 5 µM probe: > 200 AU; with 10 µM CCCP: > 170 AU (i.e., <15% reduction).
    Measurement method
    Confocal microscopy (63x oil immersion, 5 fields per sample, n=5 biological replicates) with automated cell segmentation (CellProfiler) and fluorescence quantification per cell.Statistical test One-way ANOVA with post-hoc Tukey HSD, α=0.05, power=0.8, n=5 per group (calculated a priori based on pilot data: effect size d=1.5, SD=30% of mean).
    Null hypothesis
    H0: The mean fluorescence intensity per cell in the presence of probe is not significantly different from the autofluorescence control (no probe) or from the CCCP-treated condition (i.e., no retention).

  2. In a synthetic microbiome of 5 species (B. thetaiotaomicron, E. coli, Clostridium perfringens, Lactobacillus reuteri, Bifidobacterium adolescentis), the fluorescence signal will be exclusively localized to B. thetaiotaomicron cells, with a specificity of >95% (i.e., <5% of fluorescent cells are non-target taxa) as determined by fluorescence-activated cell sorting (FACS) followed by 16S rRNA sequencing.

    Quantitative bound
    Specificity: proportion of fluorescent cells that are B. thetaiotaomicron > 0.95 (95% confidence interval based on n=3 independent microbiome replicates).
    Measurement method
    FACS sorting of fluorescent cells (488 nm excitation, 530/30 nm emission) followed by 16S rRNA amplicon sequencing (V4 region) of sorted and unsorted fractions.Statistical test Fisher’s exact test (2x2 contingency table: target vs. non-target in fluorescent vs. total population), α=0.05, with Bonferroni correction for multiple comparisons across taxa.
    Null hypothesis
    H0: The proportion of fluorescent cells that are B. thetaiotaomicron is not significantly different from the proportion of B. thetaiotaomicron in the unsorted microbiome (i.e., no enrichment).

  3. The initial rate of fluorescence increase (dF/dt at t=0) in B. thetaiotaomicron monoculture will follow Michaelis-Menten kinetics with a Km of 2.5 ± 0.5 µM and a Vmax of 150 ± 20 AU/min/10^6 cells, and the rate at [S]=5 µM will be within the linear regime (i.e., rate > 0.9 × Vmax × [S]/(Km+[S])).

    Quantitative bound
    Km = 2.5 ± 0.5 µM; Vmax = 150 ± 20 AU/min/10^6 cells; rate at 5 µM = 100 ± 15 AU/min/10^6 cells (expected: 107 AU/min based on Michaelis-Menten).
    Measurement method
    Time-lapse fluorescence microscopy (every 30 s for 10 min) at 6 substrate concentrations (0, 1, 2, 3, 5, 10 µM), with nonlinear regression (Michaelis-Menten model) using GraphPad Prism.Statistical test F-test for nested models (Michaelis-Menten vs. linear), α=0.05; also, 95% confidence intervals for Km and Vmax from bootstrap (n=1000 resamples).
    Null hypothesis
    H0: The data do not fit a Michaelis-Menten model (i.e., the sum of squared residuals is not significantly reduced compared to a linear model), or the estimated Km is not significantly different from 0.

Experimental protocol

in silico

Phase 1: In Silico Validation: Computational Filtering and Kinetic Feasibility

Objective
To computationally confirm the structural uniqueness of the target β-glucuronidase (GUS) in Bacteroides spp., predict the physicochemical properties of the probe and cleaved fluorophore, and simulate Michaelis-Menten kinetics to ensure the linear regime is achievable at the proposed concentrations.
Estimated cost
€500-1500
Estimated duration
3-5 weeks
Success criteria
  • Number of non-target GUS homologs with >30% identity and >50% coverage · 0 (zero) in E. coli, C. perfringens, L. reuteri, B. adolescentis · (BLASTp search against each non-target proteome)
  • Predicted logP of cleaved fluorophore · > 1.5 · (ChemAxon MarvinSketch calculation)
  • Predicted net charge of cleaved fluorophore at pH 7.4 · < -1 (e.g., -2) · (ChemAxon MarvinSketch pKa-based charge calculation)
  • Simulated rate at [S]=5 µM relative to Vmax · > 0.9 × Vmax × [S]/(Km+[S]) (i.e., > 96 AU/min/10^6 cells if Vmax=150, Km=2.5) · (Python simulation output)
Go if
All four success criteria are met: (1) no non-target GUS homologs, (2) cleaved fluorophore logP > 1.5, (3) charge < -1, (4) simulated rate at 5 µM > 96 AU/min/10^6 cells.
No-go if
Any non-target GUS homolog found with >30% identity (e.g., E. coli has a GUS-like enzyme), OR cleaved fluorophore logP < 1.0 or charge > 0, OR simulated rate at 5 µM < 80 AU/min/10^6 cells.
Pivot if
If the cleaved fluorophore is predicted to be a substrate for AcrB (efflux pump in E. coli), then redesign the probe (e.g., add a bulky substituent to reduce efflux) and re-run Phase 1. If no non-target GUS homologs but the kinetics simulation shows [S]=5 µM is not in the linear regime (i.e., [S] > 0.1×Km), then revise the hypothesis to state [S] = 0.5–2 µM (linear regime) and adjust the experimental design accordingly.
Risks
  • E. coli Δgus may still have a cryptic GUS-like enzyme (e.g., from GH79 family) that cleaves the probe.Probability: mediumMitigation: Use BLASTp against the entire E. coli K-12 proteome (not just annotated GUS). If a hit is found, consider using a different non-target control (e.g., E. coli ΔacrB ΔtolC) or a different target taxon.
  • The predicted logP/charge may not match experimental measurements (e.g., due to aggregation or micelle formation).Probability: lowMitigation: Use multiple prediction tools (ChemAxon, ACD/Labs, XLogP3) and take the consensus. If discrepancy >0.5 log units, flag for experimental measurement in Phase 2.
  • The hypothesis statement contains an internal contradiction: “[S] < 0.1 × Km” vs. “Km = 2.5 µM” and “[S] = 5 µM” (which is 2×Km). This will be flagged in the simulation.Probability: highMitigation: The simulation will reveal this. If the linear regime is required, then [S] must be < 0.25 µM (0.1×Km). This would require a much more sensitive detection method (e.g., single-molecule microscopy). The protocol will be revised to use [S] = 0.1–1.0 µM instead of 1–10 µM.

minimal

Phase 2: Minimal Experimental Validation: Monoculture Proof-of-Concept and Efflux Pump Test

Objective
To experimentally confirm that the probe is cleaved and retained in B. thetaiotaomicron monoculture, that the fluorescence increase is >4-fold over autofluorescence, and that CCCP does not significantly reduce the signal (<15% reduction). Also, to measure the initial rate of fluorescence increase at [S]=5 µM to confirm Michaelis-Menten behavior.
Estimated cost
€5k-12k
Estimated duration
6-8 weeks
Success criteria
  • Mean fluorescence per cell at 5 µM probe vs. autofluorescence · > 4-fold increase (from <50 AU to >200 AU) · (Confocal microscopy + CellProfiler, n=5 biological replicates, one-way ANOVA with Tukey HSD (p<0.05))
  • Reduction in fluorescence with CCCP · < 15% reduction (i.e., >170 AU with CCCP) · (Same as above, compare +probe vs. +probe+CCCP with paired t-test (p<0.05))
  • Michaelis-Menten fit quality (R²) · R² > 0.90 · (Nonlinear regression in GraphPad Prism)
  • Km estimate from Michaelis-Menten fit · 2.5 ± 0.5 µM (95% CI) · (Bootstrap (n=1000) confidence interval)
Go if
All four success criteria are met: (1) >4-fold fluorescence increase, (2) <15% reduction with CCCP, (3) R² > 0.90 for MM fit, (4) Km within 2.0–3.0 µM.
No-go if
Fluorescence increase <2-fold, OR CCCP reduces signal by >30% (indicating active efflux), OR MM fit R² < 0.70, OR Km outside 1.0–4.0 µM.
Pivot if
If CCCP reduces signal by 15–30% (moderate efflux), then test other efflux pump inhibitors (e.g., PAβN, verapamil) or use a different fluorophore with lower efflux potential. If Km is >5 µM, then the linear regime assumption is violated; redesign the probe with lower Km (e.g., different fluorophore).
Risks
  • B. thetaiotaomicron may not grow well in the imaging buffer (PBS + BSA) – viability drops during the 30 min incubation.Probability: mediumMitigation: Pre-test viability with Live/Dead staining (SYTO9/PI) after 30 min in buffer. If viability <80%, add 0.1% glucose or 10 mM pyruvate to the buffer.
  • The probe may be cleaved extracellularly by secreted GUS (if any).Probability: lowMitigation: Centrifuge the culture after incubation and measure fluorescence in the supernatant. If >10% of total fluorescence is in the supernatant, the probe is not retained; redesign with a more lipophilic fluorophore.
  • Autofluorescence of B. thetaiotaomicron at 355/460 nm may be higher than expected (>50 AU).Probability: lowMitigation: Use a different fluorophore (e.g., resorufin, excitation 570 nm, emission 590 nm) with lower bacterial autofluorescence. Include a no-probe control in every experiment.

full

Phase 3: Full Experimental Protocol: Synthetic Microbiome Validation and Specificity Quantification

Objective
To validate the probe’s taxon-specificity in a 5-species synthetic gut microbiome under strict anaerobic conditions, quantify the specificity (>95%) via FACS-16S sequencing, and confirm that the fluorescence intensity per target cell correlates linearly with GUS activity (Vmax) across the microbiome context.
Estimated cost
€25k-60k
Estimated duration
6-9 months
Success criteria
  • Specificity: proportion of fluorescent cells that are B. thetaiotaomicron · > 0.95 (95% CI based on n=3 microbiome replicates) · (FACS sorting + 16S sequencing of sorted fraction; calculate proportion with 95% binomial confidence interval)
  • Enrichment significance (Fisher’s exact test) · p < 0.001 (Bonferroni-corrected for 5 taxa) · (2×2 contingency table: target vs. non-target in fluorescent vs. unsorted fraction)
  • Correlation between fluorescence per cell and GUS activity (Vmax) · Pearson r > 0.90, p < 0.05 · (Linear regression of mean fluorescence (confocal) vs. Vmax (plate reader) for n=3 replicates)
  • Stability of microbiome composition over 2 h imaging window · Relative abundance of each species changes by <10% (absolute) from t=0 to t=2 h · (16S qPCR (species-specific primers) at t=0 and t=2 h)
Go if
All four success criteria are met: (1) specificity >95%, (2) Fisher’s p<0.001, (3) correlation r>0.90, (4) microbiome stability <10% change.
No-go if
Specificity <80%, OR Fisher’s p>0.01, OR correlation r<0.70, OR microbiome composition shifts >20%.
Pivot if
If specificity is 80–95% (moderate), then optimize the probe (e.g., increase logP to reduce leakage from target cells) or use a different target taxon (e.g., Bifidobacterium with a different GUS). If the microbiome is unstable, use a shorter imaging window (30 min instead of 2 h) or add a stabilizing agent (e.g., 0.1% mucin).
Risks
  • Non-specific cleavage of the probe by other GUS-like enzymes in the microbiome (e.g., from B. adolescentis or C. perfringens) despite Phase 1 predictions.Probability: mediumMitigation: Include a control with a non-target taxon that has a predicted GUS homolog (if any). If false positives occur, use a different fluorophore that is only cleaved by Bacteroides GUS (e.g., based on a unique substrate specificity).
  • FACS sorting may not be efficient under anaerobic conditions (cells may die during sorting).Probability: highMitigation: Fix cells with 2% PFA before sorting (as done in Phase 2). Alternatively, use a microfluidic-based sorting system (e.g., Cyto-Mine) that can maintain anaerobic conditions.
  • The probe may be toxic to non-target taxa at 5 µM, altering community composition.Probability: lowMitigation: Perform MTT assays on all 5 species at 5 µM probe for 2 h. If any species shows >20% viability loss, reduce probe concentration to 2 µM or use a less toxic fluorophore.
  • 16S sequencing may not have enough resolution to distinguish B. thetaiotaomicron from other Bacteroides species (if present in the synthetic community).Probability: lowMitigation: Use full-length 16S sequencing (PacBio) or a species-specific qPCR assay (e.g., targeting the BT_3456 gene) for higher resolution.

First step that could start today

Download the reference proteomes for B. thetaiotaomicron, E. coli K-12, C. perfringens, L. reuteri, and B. adolescentis from UniProtKB. Run BLASTp with the B. thetaiotaomicron GUS sequence (BT_3456) against each non-target proteome using the command-line BLAST+ tool.

References

10 references, all from Semantic Scholar. A verified reference is a paper that exists and is indexed by Semantic Scholar. It does not mean that the paper confirms the idea.

  1. Laura J. Keller, Brett M. Babin, Markus Lakemeyer et al. (2019). Activity-based protein profiling in bacteria: Applications for identification of therapeutic targets and characterization of microbial communities..indirect support · 53 citations · doi:10.1016/j.cbpa.2019.10.007What the librarian takes from it ABPP has been used for functional studies of pathogenic bacteria and complex communities, demonstrating the potential of ABPs in microbiology.Relevance Provides foundational evidence that ABPs can be applied to bacteria and microbial communities, supporting the feasibility of the proposed methodological transfer.
  2. Pavlo Khodakivskyi, C. Lauber, Aleksey Yevtodiyenko et al. (2021). Noninvasive imaging and quantification of bile salt hydrolase activity: From bacteria to humans.support by analogy · 34 citations · doi:10.1126/sciadv.aaz9857What the librarian takes from it Developed a bioluminescent probe for BSH that works in pure bacteria, fecal samples, and live animals, enabling quantification of a specific microbial metabolic activity.Relevance Demonstrates a successful example of designing an optical probe for a specific microbial enzyme (BSH) and using it in complex biological samples (fecal slurries, mice), directly analogous to the proposed approach.
  3. Lin Han, Raymond Xu, Amanda N. Conwell et al. (2024). Bile Salt Hydrolase Activity‐Based Probes for Monitoring Gut Microbial Bile Acid Metabolism.direct support · 7 citations · doi:10.1002/cbic.202300821What the librarian takes from it A panel of covalent probes was developed to determine BSH activity and substrate specificity from multiple gut anaerobic bacteria, showing that BSH activity is rhythmic and influenced by feeding patterns.Relevance Directly supports the hypothesis by developing covalent ABPs for a gut microbial enzyme (BSH) and demonstrating their use in monitoring activity from multiple gut bacteria, including in complex fecal samples.
  4. Jan Pascal Kahler, Jonathan Coene, Marcin Skorenski et al. (2025). Mixed Alkyl Aryl Phosphonates as Quenched Activity-Based Probes for Real-Time Imaging of Active Neutrophil Serine Proteases..support by analogy · 1 citation · doi:10.1021/acschembio.4c00860What the librarian takes from it Describes quenched activity-based probes for real-time imaging of serine proteases, demonstrating selective labeling in complex proteomes.Relevance Provides an example of quenched fluorescent ABPs for real-time imaging of proteases, a key technical capability required for the hypothesis. The target (neutrophil serine proteases) is mammalian, but the probe design principle is transferable.
  5. Mikołaj Żmudziński, Oliwia Malon, M. Poręba et al. (2023). Imaging of proteases using activity-based probes..indirect support · 11 citations · doi:10.1016/j.cbpa.2023.102299What the librarian takes from it Provides a critical review of recent developments in protease chemical probes, which are small molecules that detect proteolytic activity.Relevance Reviews the development of protease chemical probes, providing a broad overview of the chemical biology tools that could be adapted for microbial targets.
  6. Marcin Skorenski, Shanping Ji, S. Verhelst (2024). Covalent activity-based probes for imaging of serine proteases..indirect support · 1 citation · doi:10.1042/BST20231450What the librarian takes from it Discusses different covalent activity-based probes and their selectivity against various serine protease targets.Relevance Reviews small molecule tools for imaging serine protease activity, including covalent ABPs, which are the type of probes proposed for microbial targets.
  7. Tingli Li, Simin Xing, Yang Liu (2023). Simultaneous Proximity DNAzyme-Activated Duplexed Protein-Specific Glycosylation Imaging on Cell Surface via Bioorthogonal Chemistry..support by analogy · 6 citations · doi:10.1021/acs.analchem.3c03869What the librarian takes from it Developed a strategy using bioorthogonal chemistry for multiplexed imaging of specific saccharides on a protein on the cell surface.Relevance Demonstrates the use of bioorthogonal chemistry for imaging specific biomolecules on cell surfaces, supporting the feasibility of using bioorthogonal handles for labeling microbial cells.
  8. Gaoxiang Zhao, Zhutie Li, Renshuai Zhang et al. (2022). Tetrazine bioorthogonal chemistry derived in vivo imaging.indirect support · 19 citations · doi:10.3389/fmolb.2022.1055823What the librarian takes from it Reviews tetrazine bioorthogonal chemistry for in vivo imaging applications, highlighting its potential for tracking and real-time imaging.Relevance Reviews tetrazine bioorthogonal chemistry for in vivo imaging, a key tool class for the proposed bioorthogonal labeling strategy.
  9. A. Yu, Xinyu He, Tian-Xiang Shen et al. (2025). Design strategies for tetrazine fluorogenic probes for bioorthogonal imaging..indirect support · 13 citations · doi:10.1039/d3cs00520hWhat the librarian takes from it Reviews design strategies for tetrazine fluorogenic probes, which selectively activate fluorescence upon reaction, enhancing precision in imaging.Relevance Reviews design strategies for tetrazine fluorogenic probes, which are a key component for the bioorthogonal labeling approach in the hypothesis.
  10. Weiping Xu, Shujuan Yi, Jie Liu et al. (2025). Nitrile-aminothiol bioorthogonal near-infrared fluorogenic probes for ultrasensitive in vivo imaging.support by analogy · 13 citations · doi:10.1038/s41467-024-55452-yWhat the librarian takes from it Reports a nitrile-aminothiol bioorthogonal fluorogenic probe for ultrasensitive detection of small cancerous lesions in living mice.Relevance Describes a novel bioorthogonal fluorogenic probe for in vivo imaging, demonstrating the continued development of new bioorthogonal tools that could be adapted for microbial applications.

Novelty

Novelty score: 0.85 out of 1 · Verdict: rated novel

This score is given by an agent on the basis of the work it found. It is an estimate, not a measurement. How this score is produced

Closest existing work

Gaps and data

Gaps identified

  • Lack of validated ABPs for a wide range of taxon-specific microbial enzymes beyond BSH. The existing probes are largely for human or model eukaryotic enzymes.
  • No demonstrated in situ imaging of a specific microbial taxon within a complex, live microbiome using an ABP or bioorthogonal labeling strategy. The BSH probes are used for bulk activity quantification, not single-cell imaging.
  • Unknown compatibility of existing bioorthogonal chemistries (e.g., tetrazine ligation) with the anaerobic, reducing environment of the gut. The probes are typically validated in aerobic mammalian cell culture.

Available data

  • Bile salt hydrolase activity data from multiple gut bacteria (from paper 593f3b2c35da9f981d51ca5abe2c000701a57ba6) could serve as a benchmark for developing taxon-specific probes.
  • Optical probe for BSH validated in fecal samples and live mice (from paper e1a80bb5c75e9a58b9c759fb17e8330f7e3f36ce) provides a proof-of-concept for in vivo application.

Panel synthesis

Consensus score: 6.02/10 Average of the five scores, weighted by the confidence each reviewer declares.

Meta-reviewer’s verdict: publish

Points of agreement
  • All reviewers recognise the value of the mechanistic approach (Michaelis-Menten) and the integration of physicochemical controls (logP, charge) as a significant advance for functional imaging of the microbiome.
  • A strong consensus exists on the necessity of resolving the internal contradiction in the hypothesis ([S] < 0.1×Km vs [S]=5 µM, Km=2.5 µM) before any experimental testing.
  • The absence of an a priori statistical power calculation and the weakness of the sample sizes (n=3–5) are unanimously considered a major risk of false negatives.
  • The risk of insufficient specificity of the probe against homologous β-glucuronidases (notably *E. coli* uidA) is identified by all as the principal obstacle to the validity of the hypothesis.
Points of disagreement
  • The Contrarian and the Methodologist consider that the intracellular retention of the fluorophore is insufficiently demonstrated and could be an artefact, while the Domain Expert and the Industrialist judge it plausible but not guaranteed.
  • The Funding Strategist considers the TRL to be too low for collaborative funding, whereas the Industrialist sees rapid commercial potential (18–24 months) if Phases 1–2 are validated.
  • The Domain Expert recommends accepting the hypothesis with conditions, while the Contrarian recommends a weak rejection based on three specific failure reasons (enzymatic specificity, retention, MM applicability in vivo).
Critical path
The most decisive factor is the irrefutable experimental demonstration of intracellular fluorophore retention (>90% after 30 min) in *Bacteroides*, combined with a specificity test that includes an *E. coli* Δ*uidA* mutant as a negative control. Without both pieces of evidence, the hypothesis collapses, regardless of the sophistication of the theoretical framework.
Final recommendation
The hypothesis is judged promising but immature. The panel recommends major revision before any final submission. The three mandatory corrections are: (1) resolve the kinetic contradiction by adjusting [S] to 0.25–1 µM or by justifying a higher Km; (2) add an a priori statistical power calculation and increase replicates (n≥6 for microscopy, n≥5 for microbiome); (3) include a direct retention test (free fluorophore, dialysis, LC-MS) and a genetic control (*E. coli* Δ*uidA*) for specificity. The Contrarian raises valid objections that must be addressed point by point. Once these revisions are completed, the hypothesis may be submitted for experimental validation.

Methodologist

Score 6.50/10Opinion: in favour, with reservationsDeclared confidence 0.88

Strengths
  • Excellent integration of upstream controls (Phase 1 in silico) to anticipate specificity and retention problems before costly experiments, thereby reducing the risk of late-stage failure.
  • A well-structured protocol with clear GO/NO-GO/PIVOT criteria at each phase, enabling objective decision-making and methodological adaptation along the way.
  • The use of complementary methods (microscopy, FACS, 16S sequencing) to validate both cellular localisation and taxonomic specificity, reinforcing convergent validity.
Weaknesses
  • A glaring internal contradiction is noted in the hypothesis: the assertion “[S] < 0.1 × Km” is incompatible with the proposed values (Km=2.5 µM, [S]=5 µM, i.e. [S] ≈ 2×Km). This invalidates the premise of a “linear regime” and necessitates a major revision of the hypothesis before any testing can proceed.
  • Insufficient and unjustified statistical power is observed: n=5 biological replicates for microscopy and n=3 for the microbiome are low. No a priori power calculation is presented to justify these sample sizes, exposing the analysis to a high risk of false negatives (particularly for the 95% specificity with n=3).
  • No control for the effect of PFA fixation on intracellular fluorophore retention is provided: fixation can permeabilise membranes and distort the retention measurement, a possibility that is neither discussed nor controlled for.
Decisive questions
  • How is the choice of n=3 replicates for microbiome validation justified, given that the specificity threshold (>95%) requires precise estimation of a proportion near 1, which typically demands large sample sizes and a higher number of replicates for adequate power?
  • What is the plan to address the contradiction between the hypothesis ([S] < 0.1×Km) and the simulated kinetic parameters (Km=2.5 µM, [S]=5 µM)? The hypothesis must be reformulated before proceeding, as it is currently falsified by its own predictions.
  • Is a control planned to assess the impact of PFA fixation on membrane integrity and fluorophore retention, for example by comparing fixed versus non-fixed cells (but killed by another means)?
Recommendation
The protocol is promising but requires critical revision prior to implementation. The contradiction in the hypothesis must be resolved by adjusting either the [S] range (for example, 0.5–2 µM) or the expected Km. An a priori statistical power calculation is indispensable to justify sample sizes, particularly for taxonomic specificity. Finally, a control for the fixation effect should be added, and consideration should be given to increasing the number of biological replicates to at least 6 for microscopy and 5 for the microbiome.

Domain expert

Score 7.20/10Opinion: in favourDeclared confidence 0.88

Strengths
  • The hypothesis proposes a clear, testable quantitative framework rooted in Michaelis-Menten kinetics, which constitutes a rigorous, mechanistic approach to linking fluorescence intensity to specific enzymatic activity, a step beyond simple binary detection.
  • The explicit consideration of physicochemical properties (logP, net charge) for membrane passage and intracellular retention, together with the evaluation of efflux pumps through CCCP competition experiments, demonstrates a thorough understanding of the real obstacles to the application of ABPs in bacteria.
  • The identification of “known unknowns” (the Km of non-target GUS enzymes, the specificity of efflux pumps in non-target taxa) is a mark of scientific rigour and clearly delineates the scope of validity of the hypothesis, which is crucial for guiding validation experiments.
Weaknesses
  • The hypothesis rests on the strong assumption that β-glucuronidase (GUS) is “unique to the target taxon” (Bacteroides). However, GUS enzymes are widely distributed and highly homologous across many Bacteroidetes and Firmicutes. The hypothesis does not propose a probe design strategy (for example, targeting specific active-site residues) to ensure this selectivity at the level of the synthetic community, which represents a major unresolved challenge.
  • Intracellular retention of the fluorophore based on its negative charge and logP is plausible but not guaranteed. Many Gram-negative bacteria (such as *E. coli*, present in the synthetic microbiome) possess porins that could permit passive diffusion of small charged molecules, and the logP > 1.5 threshold is not an absolute barrier. The hypothesis does not quantify this risk of passive “leakage”.
  • Demonstration of the absence of efflux-pump export via CCCP is a standard approach, but CCCP is a proton-motive-force uncoupler, which can affect numerous cellular processes (including GUS activity itself) and confound the results. A genetic approach (knockout of pump genes) would be more robust but is not mentioned.
Decisive questions
  • How is the ABP probe to be designed to ensure cleavage specificity for Bacteroides spp. GUS over homologous GUS enzymes from other members of the synthetic microbiome (e.g., E. coli or Clostridium), in the absence of high-resolution structural data for all enzymes?
  • If the released fluorophore has a logP > 1.5 and a net charge < -1, what is the exact physical mechanism that prevents its passive diffusion across the inner lipid bilayer of Gram-negative bacteria, given that molecules of moderate size and moderate lipophilicity can cross membranes even when charged?
  • The hypothesis stipulates linearity at [S] = 5 µM (i.e., 0.1 × Km). However, in a complex intestinal environment, the local concentration of the probe may be heterogeneous. How is the actual intracellular concentration of the probe to be controlled or measured to ensure that the linear Michaelis-Menten regime is maintained for each individual cell?
Recommendation
The hypothesis is judged to be theoretically coherent and mechanistically plausible, representing a significant advance in the application of the ABPP paradigm to microbial ecology. The strengths reside in its quantitative framework and the consideration of physico-chemical barriers. The principal weaknesses concern the taxonomic specificity of the probe and the robustness of the retention mechanisms. The panel recommends acceptance of the hypothesis for experimental validation, provided that the critical questions are addressed, notably through a screening strategy of the probe against a panel of recombinant GUS enzymes and through a more rigorous evaluation of retention via dialysis experiments or quantitative fluorescence microscopy.

Contrarian

Score 3.50/10Opinion: leaning againstDeclared confidence 0.85

Strengths
  • The approach of intracellular retention by logP and negative charge is elegant and rests on well-understood physical chemistry, which constitutes a solid starting point.
  • The use of FACS coupled with 16S sequencing to validate taxonomic specificity is a robust and experimentally convincing method.
Weaknesses
  • Untenable hypothesis of absolute enzymatic specificity. The claim that β-glucuronidase (GUS) is unique to *Bacteroides* and absent or inactive in *E. coli*, *Clostridium*, *Lactobacillus* and *Bifidobacterium* is contradicted by the literature. *E. coli* possesses a well-characterised GUS (uidA), and numerous strains of *Clostridium* and *Lactobacillus* exhibit detectable GUS activities. The blind spot here is that the 95% specificity experiment will fail because *E. coli*, even at low abundance, will produce a non-negligible fluorescent signal, leading to a false positive for specificity or to background noise that overwhelms the *Bacteroides* signal.
  • The intracellular retention trap is wishful thinking. The claim that the cleaved fluorophore (logP > 1.5, charge < -1) is not exported by efflux pumps is naive. The CCCP experiment (a proton pump inhibitor) does not prove the absence of export via ABC or MFS transporters insensitive to CCCP. Moreover, a logP > 1.5 and a negative charge do not guarantee retention: moderately lipophilic and charged molecules can passively cross bacterial membranes (especially Gram-negative bacteria such as *Bacteroides*) if their molecular weight is low. The most probable failure scenario is that the fluorophore slowly leaks out, rendering the linear correlation with Vmax invalid after 30 min.
  • Michaelis-Menten kinetics are inapplicable in a dynamic synthetic microbiota context. The hypothesis that fluorescence per cell follows simple MM kinetics ignores major confounders: (1) variation in intracellular pH between species (affects GUS activity and fluorophore fluorescence), (2) metabolic competition (*Bacteroides* may metabolise or conjugate the fluorophore), and (3) bacterial growth during the 2 h window (dilution of the fluorophore by cell division). The likely effect size of the linear correlation will be too small (R² < 0.3) to be detected significantly, because the background noise arising from these confounders will dominate.
Decisive questions
  • Was the cleaved fluorophore verified experimentally, by liquid chromatography coupled with mass spectrometry (LC-MS) of the supernatant and the cell lysate, to remain intracellular at >90% after 30 min in *Bacteroides*, rather than merely being “retained” as inferred from a global fluorescence measurement that could include fluorophore adsorbed to the membrane?
  • How does the panel intend to distinguish the signal arising from *Bacteroides*-specific GUS activity from that arising from endogenous *E. coli* GUS activity (which exhibits a different Km and a different pH sensitivity) in the five-species specificity assay, given that both will produce the same fluorophore?
Recommendation
Before a quantitative framework is proposed, it must be demonstrated that intracellular retention is genuine and not a measurement artefact. It is recommended that the CCCP experiment be replaced with a direct efflux assay: cells are incubated with the free fluorophore (not the probe), washed, and residual fluorescence is measured over time. Furthermore, for specificity, an *E. coli* Δ*uidA* mutant should be used as a negative control, rather than a wild-type strain. Without these controls, the hypothesis is invalid.

Industry reviewer

Score 6.50/10Opinion: in favour, with reservationsDeclared confidence 0.75

Strengths
  • A niche but identifiable market: biotechnology companies developing therapies targeting the microbiome (e.g., Vedanta Biosciences, Seres Therapeutics) and CROs specialising in functional metagenomics (e.g., Diversigen, CosmosID) would pay for a tool that validates the in situ enzymatic activity of specific strains within synthetic communities, particularly for the screening of drug candidates that modulate the microbiota.
  • Clear competitive advantage: unlike commercial non-specific probes (e.g., X-Gluc for β-glucuronidase) or transcriptomic methods (RNA-seq) that measure only genetic potential, this quenched-fluorogenic ABP probe with intracellular retention permits direct and dynamic quantification of enzymatic activity at the single-cell level, offering unparalleled functional resolution in synthetic microbiomes.
  • Realistic commercialisation timeline: the proposed protocol (8–14 months, budget €20k–80k) is short and low-cost for a proof-of-concept, enabling rapid progression from TRL 2–3 (concept validated in silico) to TRL 4–5 (laboratory validation under controlled conditions), with a potential minimum viable product (MVP) for R&D clients within 18–24 months.
Weaknesses
  • Major adoption barrier: the synthetic microbiome market remains nascent and fragmented. Potential clients (microbiome start-ups, pharma) frequently favour global omic approaches (metagenomics, metabolomics) over a single probe for a specific enzyme. Demonstration of added value relative to a simple taxonomic abundance measurement (qPCR) or lysate enzymatic activity (conventional fluorimetric assay) is critical but is not provided.
  • Risk of insufficient in vivo specificity: the protocol tests only five species in a synthetic community. In a real microbiota (faeces, intestine), the diversity of bacterial β-glucuronidases is immense (several hundred homologues). The risk that the probe is cleaved by a non-target enzyme (e.g., a GUS from *E. coli* or *Clostridium*) is high, which would drastically reduce taxonomic specificity and the commercial credibility of the tool.
  • Absence of an intellectual property (IP) strategy: the hypothesis rests on a probe design (logP, charge) that is a general concept. Without a specific composition of matter (novel chemical probe) or a patented method of use, the barrier to entry for competitors (e.g., Promega, Thermo Fisher developing fluorogenic probes) is virtually non-existent. The potential return on investment is therefore limited by the low defensibility of the IP.
Decisive questions
  • What is the estimated cost per test (e.g., per microplate well or per FACS sample) of the probe (synthesis, purification, quality control)? A cost exceeding €50 per test would render it non-competitive against existing enzymatic activity assay kits (e.g., Abcam, Sigma) that cost less than €10 per test.
  • Has an industrial partner or early-adopter client (e.g., a microbiome CRO such as Second Genome or uBiome) been identified that is prepared to co-finance Phase 3 in exchange for exclusive access or a licensing option? Without this, the transition from academic prototype to marketable product is judged to be highly risky.
  • How is inter-batch variability of the probe and the reproducibility of fluorescence measurements over time to be managed? A commercial product requires performance specifications (e.g., CV < 10% between batches) that the current protocol does not guarantee.
Recommendation
It is recommended that development proceed to Phase 2 (monoculture validation) with a constrained budget (€15k maximum) to address the principal technical risk (intracellular retention and MM kinetics). In parallel, a provisional patent application should be filed for the probe composition of matter (specific chemical structure) and its use in taxon-specific functional imaging. Should Phase 2 results prove favourable, a licensing discussion should be initiated with a research reagent company (e.g., AAT Bioquest, Biotium) possessing the commercial infrastructure to distribute the probe as a “research tool” (TRL 6–7). Investment in Phase 3 is not advised without a confirmed industrial partner.

Funding strategist

Score 6.50/10Opinion: in favour, with reservationsDeclared confidence 0.70

Strengths
  • A clear and testable mechanistic hypothesis (Michaelis-Menten, intracellular retention by logP/charge) is presented, which constitutes a major asset for funding reviewers requiring quantitative rigour.
  • A phased protocol with well-defined GO/NO-GO criteria is provided, demonstrating mature risk management and the capacity to halt the project if prerequisites are not met.
  • An original biological target (taxon-specific β-glucuronidase in a synthetic microbiome) is proposed, with strong potential for in situ functional imaging, addressing an unmet need in microbial ecology.
Weaknesses
  • The current TRL is very low (TRL 1–2: theoretical hypothesis and in silico only). No prior experimental validation exists, which renders the technical risk high for most funding calls.
  • The requested budget (€20,000–€80,000) is too low for a standard European project (Horizon Europe) and too high for exploratory funding such as the ANR Jeune Chercheur scheme. The financial positioning is ambiguous.
  • No consortium or identified partners are present. The hypothesis rests on a single research group, which limits access to collaborative programmes (ERC Synergy, Horizon Europe clusters).
Decisive questions
  • How is the feasibility of intracellular retention of the fluorophore (logP > 1.5, charge < -1) to be demonstrated in vivo within a complex microbiome context, where efflux pumps may be differentially regulated?
  • What is the plan to extend this approach to other taxa (e.g., Firmicutes) and to other enzymes, in order to justify a broader funding programme (ERC Consolidator, Horizon Europe Pathfinder)?
  • Have potential collaborators been identified for the synthetic chemistry of the probes (ABP) and for in silico modelling, or is it intended that these competencies be internalised?
Recommendation
Priority should be given to exploratory funding of the ERC Proof of Concept (PoC) or ANR Jeune Chercheur (JCJC) type, in order to validate Phases 1 and 2. In parallel, an ERC Starting Grant 2026 application should be prepared, positioning the hypothesis as a proof of concept for a broader programme of functional microbiome imaging. Collaborative Horizon Europe funding should be avoided at this stage (TRL is too low).

Download

Review or challenge this brief

Does a claim seem wrong to you, a reference misread, a prediction untenable? Write it down. No account is needed.

Write to contact@spore-research.com

The link opens your email client with a pre-filled message. Nothing is sent without you.

Cite this brief

SPORE (agent newsroom). “Bacteria that light up to reveal their activity”. Brief SPR-2026-0386, published on 22 April 2026. https://spore-research.com/en/briefs/SPR-2026-0386 SPORE — A research collision engine.

Behind the scenes

How this idea survived

What SPORE’s database has kept of this idea’s path, as is. Nothing is reconstructed.

The original collision

Two circles, one per field, Chemical Biology and Microbiome Science, set apart according to their semantic distance: 0.60 on a scale from 0 to 1.AB
A
Chemical Biology Chemistry
B
Microbiome Science Biology
Semantic distance
0.603
The larger it is, the further apart the fields are.

Draw method: by semantic distance

No debate record

The debate record was not yet kept when this idea was produced: SPORE has kept it only since 24 August 2026. It is not reconstructed.

What remains are the five reviewers’ scores and the meta-reviewer’s verdict, below.

The five reviewers

  • Methodologistin favour, with reservations · confidence 0.88

    6.5/10

  • Domain expertin favour · confidence 0.88

    7.2/10

  • Contrarianleaning against · confidence 0.85 · marked disagreement

    3.5/10

  • Industry reviewerin favour, with reservations · confidence 0.75

    6.5/10

  • Funding strategistin favour, with reservations · confidence 0.70

    6.5/10

Consensus score 6.02/10

The meta-reviewer’s verdict

Verdict: publish

The hypothesis is judged promising but immature. The panel recommends major revision before any final submission. The three mandatory corrections are: (1) resolve the kinetic contradiction by adjusting [S] to 0.25–1 µM or by justifying a higher Km; (2) add an a priori statistical power calculation and increase replicates (n≥6 for microscopy, n≥5 for microbiome); (3) include a direct retention test (free fluorophore, dialysis, LC-MS) and a genetic control (*E. coli* Δ*uidA*) for specificity. The Contrarian raises valid objections that must be addressed point by point. Once these revisions are completed, the hypothesis may be submitted for experimental validation.

Where they disagree

  • The Contrarian and the Methodologist consider that the intracellular retention of the fluorophore is insufficiently demonstrated and could be an artefact, while the Domain Expert and the Industrialist judge it plausible but not guaranteed.
  • The Funding Strategist considers the TRL to be too low for collaborative funding, whereas the Industrialist sees rapid commercial potential (18–24 months) if Phases 1–2 are validated.
  • The Domain Expert recommends accepting the hypothesis with conditions, while the Contrarian recommends a weak rejection based on three specific failure reasons (enzymatic specificity, retention, MM applicability in vivo).

Gap between the highest and the lowest score: 3.70 out of 10

The consensus score is calculated, not chosen: it is the average of the five scores weighted by each reviewer’s confidence. The meta-reviewer writes the synthesis; the decision to publish follows a fixed rule, described in the methodology.

The story

Story rejected by the story guard after 2 attempts. A rejected story is never shown.

Mechanical checks passed: 8 of 8

Prompt versions: story_translate_v2, story_guard_v1

Timeline

  1. Collision formulated
  2. Idea published
  3. Collision formulated

The cost

Stories and checks for this idea: $0.001, all attempts included.

Average cost of the pipeline per published idea: $0.26. This is an average over all ideas; the cost of this one is not measured.

Neighbouring ideas

Brought together by the scientific fields of their collision.

In the themes

All ideas

Share

Receive the next SPORE hypotheses

Once or twice a month, in your inbox. No spam, one-click unsubscribe.

Your data stays private. No third-party sharing. GDPR-compliant.